R&D

R&D

CDMO

CDMO

IP STRATEGY

IP STRATEGY

ABOUT US
Cellular Nutrition & Anti-Aging Experts

CH LABS is a seasoned biotech with 50 years’ experience. Our focus and expertise is designing and developing solutions specific to cellular building blocks, nutrition, and bioavailable delivery systems. Today CH LABS is specialized contract development and manufacturing organization with an exclusive library of anti-aging formulas and protocols. Our range of innovative products cover a robust framework of application for skincare, dietary supplements, serums, rehydration drinks, and food additives. We produce a broad range of formats from topical emulsions, capsules, soft-gel encapsulation, powder, gummies, to drinkable ampoules and tinctures.

REVERSING CELLULAR AGING

Collaborate With Us

No Data Found

We Deliver Innovative Solutions

RESEARCH AND DEVELOPMENT

DELIVERY SYSTEMS

The organic unbinding of proteins, vitamins, and minerals to extract free-amino acids.

BIOMARKERS

The careful integration of OMICS to identify which proteins, peptides, and minerals have progenitor and target specific nutrients (amino-acids) for each organ of the body.

CYTOTHERAPY

The implementation and use of progenitor target specific amino-acid requirements, extracted from Bovine organs (placenta), to develop organic specific cell proteins and their regenerative benefits.

APPLICATION AREAS

We our library of BioMarkers we have designed specific formulas comprised of additives, nutritional dietary supplements, skincare, and haircare protocols.

METHODS & PROTOCOLS
0
EXPRESSED SEQUENCES
0
FORMULAS DEVELOPED
0
USE CASES
0

NEWS

Learn About Our Leading Technologies

Your request answered within 24 hours

INQUIRES

CH LABS licensing models add value by way of reducing internal R&D inputs 30% while aligning our EBITDA to profit.

Dr. Emerson,Ph.D CFO, Skincare Manufacture

CH LABS licensing models add value by way of reducing internal R&D inputs 30% while aligning our EBITDA to profit.

Dr. Emerson,Ph.D CFO, Skincare Manufacture

CH LABS licensing models add value by way of reducing internal R&D inputs 30% while aligning our EBITDA to profit.

Dr. Emerson,Ph.D CFO, Skincare Manufacture
Scroll to Top